BTIG Reiterates Buy Rating on ORIC Pharmaceuticals, Keeps $26 Target
BTIG reiterated its Buy rating and $26 price target on ORIC Pharmaceuticals. The target implies 188.9% upside from the stock’s Oct. 27 close of $9.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.